FDA Warns Ozempic Manufacturer About Misleading Advertising

The U.S. drug regulator has sent multiple warning letters to drugmaker Novo Nordisk in recent months.

Boxes of the diabetes drug Ozempic rest on a pharmacy counter in Los Angeles, on April 17, 2023. Mario Tama/Getty Images

The Food and Drug Administration (FDA) sent another warning to drug giant Novo Nordisk over an advertisement for weight loss drug Ozempic, saying the ad contains false and misleading claims.

In a letter dated Feb. 26, the FDA said the video contains misbranding of Ozempic, which in turn makes distributing the drug in violation of federal law.